Abstract
Intranasal diamorphine is a rapid, effective, analgesia, with few side effects, giving it multiple advantages over other forms of analgesia. It is also importantly a needle free alternative, acceptable to children, parents and medical staff. Due to these advantages, it is thought to be increasingly used in Paediatric A, and possibly the most popular analgesia for severe acute pain, despite being unlicensed. However, there is little quantified data on the extent of its usage. In order to clarify this, we surveyed all 214 NHS A departments in England in Wales with the scenario of an uncomplicated long bone fracture. There were 116 responses (75% return rate), showing that 60% of departments were using intranasal opioid (90% diamorphine) as 1st line and 70% as 1st or 2nd line analgesia for long bone fracture. When compared to any other drugs used, intranasal diamorphine was nearly four times more likely to be used as the 1st line analgesia. Despite being unlicensed, intranasal diamorphine is widely accepted and the most commonly used analgesia in Paediatric A for acute pain in long bone fracture. This article also reviews the literature on intranasal diamorphine with an emphasis on Paediatric usage.
Keywords: Intranasal, diamorphine, paediatric, analgesia, otitis media, Opioids, oral morphine, nauseated, vomiting patient, fentanyl, morphine
Current Pediatric Reviews
Title: Intranasal Diamorphine Usage in Paediatric Accident and Emergency
Volume: 6 Issue: 3
Author(s): Maya Kerr and Ian Maconochie
Affiliation:
Keywords: Intranasal, diamorphine, paediatric, analgesia, otitis media, Opioids, oral morphine, nauseated, vomiting patient, fentanyl, morphine
Abstract: Intranasal diamorphine is a rapid, effective, analgesia, with few side effects, giving it multiple advantages over other forms of analgesia. It is also importantly a needle free alternative, acceptable to children, parents and medical staff. Due to these advantages, it is thought to be increasingly used in Paediatric A, and possibly the most popular analgesia for severe acute pain, despite being unlicensed. However, there is little quantified data on the extent of its usage. In order to clarify this, we surveyed all 214 NHS A departments in England in Wales with the scenario of an uncomplicated long bone fracture. There were 116 responses (75% return rate), showing that 60% of departments were using intranasal opioid (90% diamorphine) as 1st line and 70% as 1st or 2nd line analgesia for long bone fracture. When compared to any other drugs used, intranasal diamorphine was nearly four times more likely to be used as the 1st line analgesia. Despite being unlicensed, intranasal diamorphine is widely accepted and the most commonly used analgesia in Paediatric A for acute pain in long bone fracture. This article also reviews the literature on intranasal diamorphine with an emphasis on Paediatric usage.
Export Options
About this article
Cite this article as:
Kerr Maya and Maconochie Ian, Intranasal Diamorphine Usage in Paediatric Accident and Emergency, Current Pediatric Reviews 2010; 6 (3) . https://dx.doi.org/10.2174/157339610793743903
DOI https://dx.doi.org/10.2174/157339610793743903 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regeneration of Pancreatic β-Cells in vivo as a Potential Therapeutic Approach for Diabetes Mellitus
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Microglial dependent protective effects of neuroactive steroids
CNS & Neurological Disorders - Drug Targets Inhibitors of Tyrosine Kinases in the Treatment of Psoriasis
Current Pharmaceutical Design Bisphosphonates-Anti-Inflammatory Properties
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Sugar-Borate Esters – Potential Chemical Agents in Prostate Cancer Chemoprevention
Anti-Cancer Agents in Medicinal Chemistry Molecular Pathophysiology of Cavernous Nerve Injury and Identification of Strategies for Nerve Function Recovery After Radical Prostatectomy
Current Drug Targets The Microbiota-Gut-Brain Axis in Neuropsychiatric Disorders: Pathophysiological Mechanisms and Novel Treatments
Current Neuropharmacology Epigallocatechin-3-Gallate Prevents Autoimmune-Associated Down- Regulation of p21 in Salivary Gland Cells Through a p53-Independent Pathway
Inflammation & Allergy - Drug Targets (Discontinued) Oyster Mushroom Laccase Inhibits Hepatitis C Virus Entry into Peripheral Blood Cells and Hepatoma Cells
Protein & Peptide Letters Mitochondrial Contributions to Aging in the Nematode Caenorhabditis elegans
Current Genomics Protein Misfolding in Disease: Cause or Response?
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Lipids at the Cross-road of Autoimmunity in Multiple Sclerosis
Current Medicinal Chemistry Ex vivo Skin Permeation Evaluation of An Innovative Transdermal Vehicle Using Nimesulide and Piroxicam as Model Drugs
Current Drug Delivery Polymeric Carriers for Gene Delivery: Chitosan and Poly(amidoamine) Dendrimers
Current Pharmaceutical Design Neurovascular Complications of Ovarian Hyperstimulation Syndrome (OHSS): From Pathophysiology to Recent Treatment Options
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Therapeutic Angiogenesis for Peripheral Artery Diseases by Autologous Bone Marrow Cell Transplantation
Current Pharmaceutical Design Cytokine Targeting in Osteoarthritis
Current Drug Targets Electric cable: cytoskeleton as an electric transmitter for cancer therapy
Current Signal Transduction Therapy A Hypothesis for Regenerative Therapy for Neuronal Disease: Stem Cells within Artificial Niche
Current Signal Transduction Therapy Prevention of Allergic Rhinitis by Aldose Reductase Inhibition in a Murine Model
Inflammation & Allergy - Drug Targets (Discontinued)